Hulsman, Max (2021) CAR T cells in cancer immunotherapy; A review on the prodigy of modern cancer treatment. Bachelor's Thesis, Life Science and Technology.
|
Text
bLST_2021_HulsmanMPM.pdf Download (1MB) | Preview |
|
Text
toestemming.pdf Restricted to Registered users only Download (114kB) |
Abstract
Over the past decades, significant advances have been made in the field of cancer treatment as novel immunotherapies made their entrance. In particular cell based immunotherapies targeting tumor associated antigens (TAAs) have evolved exceedingly. Strategies in which autologous T cells are genetically engineered in vitro to express a TAA recognizing chimeric antigen receptor (CAR) offer a solution for the suppressed anti-tumor responses observed in cancer. CAR T cell therapy has proven to be successful in the treatment of especially haematological malignancies, with currently 4 CAR T cell therapies being FDA approved for the treatment of acute lymphoblastic leukaemia (ALL) or diffuse large B cell lymphoma (DLBCL). Over the years the design of the CAR has been further and further fine-tuned in order to enhance CAR T cell activity and specificity, and to limit cytotoxic side effects like cytokine release syndrome (CRS) and neurological toxicity. Yet, efficacy of CAR T cells against solid tumors is still very limited due to limited tumor tissue penetration and an immune-suppressive tumor microenvironment, which constitutes a challenge in the design of next- generation CARs. In this review, I will discuss the concept of CAR T cell therapy, the various generations of CARs including their mode of action as well as their therapeutic efficacy and side effects.
Item Type: | Thesis (Bachelor's Thesis) |
---|---|
Supervisor name: | Heeringa, P. |
Degree programme: | Life Science and Technology |
Thesis type: | Bachelor's Thesis |
Language: | English |
Date Deposited: | 14 Jun 2021 13:36 |
Last Modified: | 14 Jun 2021 13:36 |
URI: | https://fse.studenttheses.ub.rug.nl/id/eprint/24567 |
Actions (login required)
View Item |